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USE OF SALVIA DIVINORUM, AN UNSCHEDULED HAL-
LUCINOGENIC PLANT: A WEB-BASED SURVEY OF 500
USERS. M. J. Baggott, BA, E. Erowid, F. Erowid, J. E. Mendelson,
MD, California Pacific Medical Center Research Institute, Erowid.org,
University of California, San Francisco, San Francisco, CA.
Salvia divinorum (SD) is a legal psychoactive plant that produces
hallucinogen-like effects through a putative kappa opiate mechanism.
We characterized the reasons, methods, and reported consequences of
SD use in a sample of 500 users (92.6% male, 23.48.7, range 13-68
years) with an on-line questionnaire. They had used 13.322.9
(range 1–250) times, usually to explore altered consciousness or to
have a spiritual/mystical experience. 80.6% probably or definitely
would use SD again. 92.6% smoked SD with 61.4% using a concen-
trated extract and 37.3% using dried leaf; effects were estimated to
last 14.112.8 minutes. Compared to other methods of altering
consciousness, SD effects were felt to be unique. Common (25%)
after-effects of SD included feelings of increased insight (47%),
improved mood (44.8%), calmness (42.2%), increased sense of con-
nection with the universe or nature (39.8%), weird thoughts (36.4%),
things seem unreal (32.4%), floating feeling (32%), increased sweat-
ing (28.2%) and body felt warm or hot (25.2%). 25.8% reported
persisting (24 hr) positive effects (usually an increased sense of
well-being) on at least 1 occasion. 4.4% had persisting negative
effects (most often anxiety). 0.6% had sought professional help for a
SD-related problem. At some point, 0.6% felt addicted to or depen-
dent upon SD; 1.2% reported strong cravings for SD; 0.4% endorsed
three DSM-IV dependence criteria. We conclude that SD is com-
monly used and merits further study.
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ORAL KETAMINE AS A POSITIVE CONTROL IN ABUSE
LIABILITY STUDIES. M. K. Romach, MSc, MD, E. M. Sellers,
MD, PhD, H. L. Kaplan, PhD, L. C. Fernandes, MSc, J. Oldenhof,
PhD, S. McDonald, PhD, Ventana Clinical Research Corporation,
Forest Research Institute, Toronto, Canada.
Background. NMDA receptor antagonists are currently being
developed for the treatment of several neurodegenerative disorders
including Alzheimer’s disease, Parkinson’s disease and neuropathic
pain conditions. Some high affinity NMDA receptor antagonists (e.g.
phencyclidine and ketamine) have dissociative properties and are
established agents of abuse. Other NMDA receptor antagonists such
as memantine, amantadine or dextromethorphan do not exhibit sig-
nificant potential for abuse. Therefore based on the pre-clinical and/or
clinical pharmacological profiles, a clinical abuse potential evaluation
may be required for a new NMDA receptor antagonist or a new
formulation of an existing NMDA receptor antagonist. Positive
(abused) control drugs such as ketamine are required in the conduct
of human abuse liability studies. Most published studies have eval-
uated intravenous ketamine as a comparator drug.
Purpose. The present study was designed to assess the subjective
effects of oral ketamine.
Methods. Twenty-nine healthy, experienced recreational drug us-
ers were given d-amphetamine (d-AMP) 20 mg p.o. in a single-
blinded within-day qualifying day in which they could receive three
doses of placebo and one dose of d-AMP. Sixteen subjects reliably
reported liking d-AMP and 11 subjects (9 males, 2 females) entered
a single-blind controlled dose escalating study in which they received
ketamine 65 mg, 100 mg or 150 mg (intravenous formulation dis-
solved in juice) or placebo-juice orally. Subjective and physiologic
measures were evaluated for up to 8 hours post-drug administration
Results. Graded dose related effects and differences from placebo
were reported across a wide range of abuse measures (e.g. VAS
feeling high, VAS liking, subjective price value, Cole ARCI eupho-
ria). Pharmacologic effect characteristics of the class (e.g. floating,
confusion) were also found. Ketamine 65 mg was readily distin-
guished from placebo on most measures. Doses of 150 mg were well
tolerated in the 4 subjects who received this dose.
Conclusions. These pharmacological data suggest that oral doses
of ketamine (60 -150 mg) can be used as positive controls for studies
for NMDA receptor antagonist mediated effects.
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COMPARATIVE AMERICAN AND JAPANESE TOBACCO
SMOKE UPTAKE PARAMETERS AFTER OVERNIGHT TO-
BACCO DEPRIVATION. E. F. Domino, MD, C. Kadoya, MD,
PhD, S. Matsuoka, MD, L. Ni, MS, K. Fedewa, University of Mich-
igan, University of Occupational and Environmental Health, Ann
Arbor, MI.
Tyndale et al. (2002) reported that Japanese, among various ethnic
groups, have a relatively high incidence of lower activity CYP2A6
genotypes and are associated with decreased risk for tobacco smok-
ing. Furthermore, a very large percentage of male Japanese smoke.
American and Japanese overnight deprived tobacco smokers were
phenotyped with respect to expired CO, plasma nicotine and cotinine,
and red cell COHb. The participants were 51 American and 55
Japanese cigarette smokers of mixed gender who met similar strict
criteria. American and Japanese female smokers had similar tobacco
uptake parameters. American and Japanese male smokers differed;
the latter had higher plasma nicotine and lower cotinine levels as well
as calculated 24 hr dose of nicotine and lower exhaled CO. Japanese
females and males were similar in all tobacco smoke uptake param-
eters. When the two racial groups were compared, irrespective of
gender, the only statistically significant differences were lower mean
exhaled CO levels and percent COHb in the Japanese. It is concluded
that Japanese males inhale cigarettes in moderation compared to
Americans.
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THE RELATION BETWEEN TOTAL AND FREE PLASMA
CONCENTRATIONS OF NUCLEOSIDE REVERSE TRAN-
SCRIPTASE INHIBITORS IN HIV-INFECTED CHILDREN. N.
Y. Rakhmanina, MD, J. N. van den Anker, MD, PhD, J. Sever, MD,
H. Spiegel, MD, PhD, S. Soldin, PhD, Children’s National Medical
Center, The George Washington University, Washington, DC.
Purpose: A significant relationship between the intracellular con-
centrations (ICC) of nucleoside reverse transcriptase inhibitors (NR-
TIs) metabolites and outcome parameters in HIV infection exists.
Variability in free plasma concentrations of NRTIs may contribute to
the variability in ICC of their triphosphate metabolites. To date no
studies have investigated the relation between total and free plasma
concentration of NRTIs. Our purpose was to determine the total and
free concentrations of lamivudine (3TC), stavudine (d4T) and
zidovudine (AZT) in plasma in HIV-infected children.
Methods: 22 pediatric patients (median age 8.9 years) were en-
rolled in the study. Unbound 3Tc, d4T, and AZT were separated by
ultrafiltration. The drug plasma concentrations were determined by
tandem-MS using Sciex APT-2000. Routine statistical methods were
used.
Results: There was a highly significant relation between total and
free plasma concentrations for all three NRTIs with a r-value of 0.995
for 3TC (3TCfreepl0.953TCtotalpl-36.51, p0.0001), a r-value of
0.924 for d4T (d4Tfreepl 0.65d4Ttotalpl-3.61, p0.0001), and a r-
value of 0.907 for AZT (AZTfreepl 0.14AZTtotalpl27.3,
p0.002).
Conclusion: This pilot study showed a significant linear correla-
tion between total and free plasma concentration of 3TC, d4T and
AZT in pediatric HIV-infected children. Future studies need to in-
vestigate the relation between free plasma concentrations of NRTIs
and ICC of their active metabolites.
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